Abstract

Hyperlipidaemia is an condition that increases the chance of coronary heart disease (CHD) and atherosclerotic disease (ASHD) in blood vessels. Hyperlipidaemia occurs in response to smoking, obesity, sedentary lifestyle, and other risk factors to extend CHD. Cardiovascular disease (CVD) is the reason for death.
 Hyperlipidaemia is divided into two broad classifications: Primary (familial) and Secondary (acquired).
 Primary hyperlipidemia has been generated by hereditary defects and climatic factors or by undisclosed mechanisms. Secondary hyperlipidemia concern to the metabolic disorders linked with the diabetes mellitus, liver complication, thyroid, and kidney complications. Hyperlipidemia also refers to as elevated levels of lipids within the blood. Circulating lipid are carried in lipoproteins that transport the lipids to varied tissues for energy use, lipid deposition, hormone production, and steroid formation. The lipoprotein consists of esterified and unesterified cholesterol, triglycerides, phospholipids, and protein. The general public who have hyperlipidemia experience no symptoms. Hyperlipidemia is most oftenly correlated with high-fat diets, a stationary lifestyle, obesity and diabetes mellitus. Four different classes of cholesterol-lowering drugs namely, statins, niacin, resins, and fibrates are available to treat hyperlipidemia; however, statins are now considered to be the first line therapy. The preventable causes of hyperlipidemia can include: Smoking, Being overweight, Physical inactivity, Steroid use, Alcohol consumption & Diet high in saturated fat, & cholesterol such as cheese, meat, fried & processed foods and egg yolk. The treatment of hyperlipidemia includes statins, bile acid sequestrants, fibric acids, niacin, and cholesterol absorption inhibitors.
 There are some of the novel drugs which are selected for the treatment of hyperlipidemia which includes: Evolocumab, Alirocumab, Bempedoic acid, Lomitapide, Evinacumab, and Sebelipase alfa.

Highlights

  • Hyperlipidemia is an condition that increases the chance of coronary heart disease and atherosclerotic disease (ASHD) in blood vessels

  • Circulating lipid are carried in lipoproteins that transport the lipids to varied tissues for energy use, lipid deposition, hormone production, and steroid formation

  • It known that atherosclerosis starts at a young age, and the number of young individuals developing atherosclerosis are on the increase, especially children with risk factors like familial hypercholesterolemia (FH) [3]

Read more

Summary

INTRODUCTION

Hyperlipidemia is an condition that increases the chance of coronary heart disease and atherosclerotic disease (ASHD) in blood vessels. Almost of men (25%) and women (42%) older than 65 years have abnormal serum total cholesterol level greater than 240 mg/dL. Cholesterol increases gradually due to declining oestrogen levels and weight gain [2]. Total cholesterol levels increase in men after the onset of puberty until 50 years old, followed by gradual line until 70 years of age. The serum cholesterol concentration is slightly on top of in men before 20 to 25 years old. Between 25 to 55 years of old, the serum cholesterol increases. Cholesterol levels in women are capable those of men between 55 and 60 years old [2]

EPIDEMIOLOGY
ETIOLOGY
CLASSIFICATION
TYPES OF HYPERLIPIDEMIA
COMPLICATIONS
OVERVIEW OF LIPID METABOLISM
PATHOGENIC FACTORS
10. GENETIC’S ARE THE MAIN PATHOLOGICAL CAUSE OF CONGENITAL HYPERLIPIDEMIA
11. METABOLIC DISORDERS – FOR SECONDARY HYPERLIPIDEMIA
12. DIAGNOSIS
13. HISTORY
14. PHYSICAL
15. TREATMENT
16. EFFECT OF DIETARY FACTORS ON SERUM LIPIDS
17. EXERCISE
20. MANAGEMENT
18. MEDICATIONS FOR HYPERLIPIDEMIA
19. COMBINATION THERAPY
21.1 Statins
21.2 Alternatives to statins
21.3 Bile Acids Sequestrants
21.4 Cholesterol Absorption Inhibitors
21.6 Nicotinic Acids
21.7 Omega-3 Fatty Acids
22. PREVENTION
23. INPATIENT MANAGEMENT
24.1 Lifestyle Management
24.2 Dietary Factors
26. NOVEL DRUGS SELECTED FOR HYPERLIPIDEMIA
27. EVOLOCUMAB AND ALIROCUMAB
28. SEBELIPASE ALFA
Findings
CONCLUSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call